Trials / Completed
CompletedNCT03960957
Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 301 (actual)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
An interventional phase 3 study to evaluate efficacy and safety of a new dilution and injection volume of AbobotulinumtoxinA treatment for glabellar lines
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AbobotulinumtoxinA | Treatment of glabellar facial lines with 50 U AbobotulinumtoxinA |
| OTHER | Placebo | Treatment of glabellar facial lines with placebo |
Timeline
- Start date
- 2019-06-17
- Primary completion
- 2019-09-27
- Completion
- 2020-04-16
- First posted
- 2019-05-23
- Last updated
- 2022-08-26
- Results posted
- 2021-05-11
Locations
11 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03960957. Inclusion in this directory is not an endorsement.